Pathfinder Cell Therapy Inc

PINK:PFND USA Biotechnology
Market Cap
$66.72K
Market Cap Rank
#51177 Global
#15860 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$0.02
About

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies… Read more

Pathfinder Cell Therapy Inc (PFND) - Total Assets

Latest total assets as of September 2015: $39.00K USD

Based on the latest financial reports, Pathfinder Cell Therapy Inc (PFND) holds total assets worth $39.00K USD as of September 2015.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Pathfinder Cell Therapy Inc - Total Assets Trend (1999–2014)

This chart illustrates how Pathfinder Cell Therapy Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

Pathfinder Cell Therapy Inc - Asset Composition Analysis

Current Asset Composition (December 2014)

Pathfinder Cell Therapy Inc's total assets of $39.00K consist of 68.9% current assets and 31.1% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 24.5%
Accounts Receivable $0.00 0.0%
Inventory $0.00 0.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $33.00K 31.1%
Goodwill $0.00 0.0%

Asset Composition Trend (1999–2014)

This chart illustrates how Pathfinder Cell Therapy Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Pathfinder Cell Therapy Inc's current assets represent 68.9% of total assets in 2014, a decrease from 93.1% in 1999.
  • Cash Position: Cash and equivalents constituted 24.5% of total assets in 2014, down from 90.7% in 1999.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 1999.
  • Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.

Pathfinder Cell Therapy Inc Competitors by Total Assets

Key competitors of Pathfinder Cell Therapy Inc based on total assets are shown below.

Company Country Total Assets
MedPacto Inc
KQ:235980
Korea ₩51.58 Billion
2H0
F:2H0
Germany €15.27 Million
Shenzhen CAU Technology Co Ltd
SHE:000004
China CN¥260.55 Million
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
China CN¥9.58 Billion
Nanhua Bio Medicine Co Ltd
SHE:000504
China CN¥841.96 Million
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
China CN¥509.14 Million
Chengzhi Shareholding Co Ltd
SHE:000990
China CN¥27.52 Billion
Hualan Biological EngineeringInc
SHE:002007
China CN¥16.27 Billion

Pathfinder Cell Therapy Inc - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.00 - 2.37

Lower asset utilization - Pathfinder Cell Therapy Inc generates 0.00x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -2938.20% - -93.23%

Negative ROA - Pathfinder Cell Therapy Inc is currently not profitable relative to its asset base.

Pathfinder Cell Therapy Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.00 0.01 0.13
Quick Ratio 0.00 0.01 0.06
Cash Ratio 0.00 0.00 0.00
Working Capital $-6.76 Million $ -5.68 Million $ -977.00K

Pathfinder Cell Therapy Inc - Advanced Valuation Insights

This section examines the relationship between Pathfinder Cell Therapy Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio -
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) -31.6%
Total Assets $106.00K
Market Capitalization $0.99 USD

Valuation Analysis

Below Book Valuation: The market values Pathfinder Cell Therapy Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Pathfinder Cell Therapy Inc's assets decreased by 31.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Pathfinder Cell Therapy Inc (1999–2014)

The table below shows the annual total assets of Pathfinder Cell Therapy Inc from 1999 to 2014.

Year Total Assets Change
2014-12-31 $106.00K -31.61%
2013-12-31 $155.00K -56.46%
2012-12-31 $356.00K -44.72%
2011-12-31 $644.00K +344.14%
2010-12-31 $145.00K -88.12%
2009-12-31 $1.22 Million -63.34%
2008-12-31 $3.33 Million -1.22%
2007-12-31 $3.37 Million -19.29%
2006-12-31 $4.18 Million +283.30%
2005-12-31 $1.09 Million -51.77%
2004-12-31 $2.26 Million +122.88%
2003-12-31 $1.01 Million +97.28%
2002-12-31 $514.00K +14.48%
2001-12-31 $449.00K -53.52%
2000-12-31 $966.00K +21.05%
1999-12-31 $798.00K --